AMRZ vs DOW

The company exhibits a Piotroski F-Score of 4/9, indicating stable but not robust financial health, while the absence of an Altman Z-Score limits distress risk assessment. Valuation metrics suggest the stock trades at a premium to both the Graham Number ($35.19) and intrinsic value ($16.52), supported by a high P/E of 22.98 versus sector peers. Despite solid operating margins and manageable leverage, earnings growth is negative year-over-year and quarterly earnings surprises have been inconsistent. Analysts recommend a 'buy' with a target price of $60.08, implying upside, but weak recent price performance and lack of dividend or insider activity temper near-term conviction.

Dow Inc. exhibits severe fundamental deterioration, highlighted by a weak Piotroski F-Score of 2/9 and negative profitability across all key margins. Despite a recent speculative price surge (+83.7% in 6 months), the company is facing shrinking revenues (-9.10% YoY) and a catastrophic collapse in EPS growth (-213.3% YoY). The dividend is currently unsustainable with a 700% payout ratio, indicating a 'dividend trap' scenario where payouts exceed earnings. The massive divergence between the bearish deterministic health scores and the bullish price action suggests a high-risk valuation bubble.